Xiamen Amoytop Biotech Co. Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003RT3
CNY
65.98
0.32 (0.49%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Net Sales
1,216.02
968.93
837.27
669.90
862.46
764.90
644.50
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
1,216.02
968.93
837.27
669.90
862.46
764.90
644.50
Raw Material Cost
0.00
78.50
65.31
51.20
57.86
55.24
44.40
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.38
0.26
0.12
0.10
0.13
0.12
Selling and Distribution Expenses
0.00
508.68
390.27
343.32
424.20
347.00
321.12
Other Expenses
0.00
10.41
10.49
6.37
9.93
7.74
6.88
Total Expenditure (Excl Depreciation)
0.00
691.71
560.72
458.36
581.51
479.75
434.41
Operating Profit (PBDIT) excl Other Income
1216
277.2
276.6
211.5
281
285.1
210.10000000000002
Other Income
0.00
-17.52
-5.59
-2.24
8.96
-1.81
0.95
Operating Profit (PBDIT)
472.20
254.63
293.36
235.88
310.54
304.62
229.44
Interest
0.00
0.38
0.26
0.12
0.10
0.13
0.12
Exceptional Items
0.00
0.48
0.55
0.04
-0.41
0.43
0.87
Gross Profit (PBDT)
0.00
890.43
771.96
618.69
804.60
709.66
600.11
Depreciation
0.00
0.00
26.59
26.59
24.76
24.76
21.96
Profit Before Tax
447.33
254.73
267.06
209.22
285.27
280.15
208.23
Tax
0.00
16.50
21.29
27.09
11.82
30.35
32.70
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
371.61
238.23
245.77
182.13
273.45
249.81
175.53
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
371.61
238.23
245.77
182.13
273.45
249.81
175.53
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
371.61
238.23
245.77
182.13
273.45
249.81
175.53
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
3,456.08
3,009.26
2,755.39
2,749.28
2,553.32
2,264.55
2,013.96
Earnings per share (EPS)
0.0
0.59
0.6
0.45
0.67
0.61
0.43
Diluted Earnings per share
0.0
0.59
0.6
0.45
0.67
0.61
0.43
Operating Profit Margin (Excl OI)
38.83%
28.09%
32.53%
31.58%
32.1%
36.82%
32.04%
Gross Profit Margin
36.79%
26.29%
35.07%
35.2%
35.95%
39.86%
35.72%
PAT Margin
30.56%
24.59%
29.35%
27.19%
31.71%
32.66%
27.24%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Dec 2025 is 25.50% vs 15.72% in Sep 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Dec 2025 is 56.00% vs -3.09% in Sep 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Dec 2025 is 73.48% vs -8.93% in Sep 2025

stock-summary

Interest

QoQ Growth in quarter ended Dec 2025 is -100.00% vs 33.33% in Sep 2025

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Dec 2025 has improved from Sep 2025

Compare Quarterly Results Of Xiamen Amoytop Biotech Co. Ltd. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
1,216.02
0
1,216.02
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,216.02
0
1,216.02
Raw Material Cost
0.00
0
0.00
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.00
0
0.00
Selling and Distribution Expenses
0.00
0
0.00
Other Expenses
0.00
0.00
0.00
Total Expenditure (Excl Depreciation)
0.00
0
0.00
Operating Profit (PBDIT) excl Other Income
1,216.02
0.00
1,216.02
Other Income
0.00
0
0.00
Operating Profit (PBDIT)
472.20
0
472.20
Interest
0.00
0
0.00
Exceptional Items
0.00
0
0.00
Gross Profit (PBDT)
0.00
0
0.00
Depreciation
0.00
0
0.00
Profit Before Tax
447.33
0
447.33
Tax
0.00
0
0.00
Provisions and contingencies
0
0
0.00
Profit After Tax
371.61
0
371.61
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
371.61
0
371.61
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
371.61
0
371.61
Equity Capital
0
0
0.00
Face Value
0.00
0
0.00
Reserves
3,456.08
0
3,456.08
Earnings per share (EPS)
0.00
0
0.00
Diluted Earnings per share
0.00
0
0.00
Operating Profit Margin (Excl OI)
38.83%
0%
0.00
38.83%
Gross Profit Margin
36.79%
0%
0.00
36.79%
PAT Margin
30.56%
0%
0.00
30.56%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 121.60 Million
in Dec 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Dec 2025 is 25.50% vs 15.72% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 40.99% vs 35.36% in Dec 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 37.16 Million
in Dec 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Dec 2025 is 56.00% vs -3.09% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 35.87% vs 46.65% in Dec 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 47.22 Million
in Dec 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Dec 2025 is 73.48% vs -8.93% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 56.56% vs 46.27% in Dec 2024

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 38.83%
in Dec 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Dec 2025 has improved from Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 has improved from Dec 2024